Your browser doesn't support javascript.
loading
Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors.
Arehart, Christopher H; Daya, Michelle; Campbell, Monica; Boorgula, Meher Preethi; Rafaels, Nicholas; Chavan, Sameer; David, Gloria; Hanifin, Jon; Slifka, Mark K; Gallo, Richard L; Hata, Tissa; Schneider, Lynda C; Paller, Amy S; Ong, Peck Y; Spergel, Jonathan M; Guttman-Yassky, Emma; Leung, Donald Y M; Beck, Lisa A; Gignoux, Christopher R; Mathias, Rasika A; Barnes, Kathleen C.
Afiliación
  • Arehart CH; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • Daya M; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • Campbell M; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • Boorgula MP; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • Rafaels N; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • Chavan S; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • David G; Rho, Inc, Durham, NC.
  • Hanifin J; Department of Dermatology, Oregon Health and Science University, Portland, Ore.
  • Slifka MK; Department of Dermatology, Oregon Health and Science University, Portland, Ore.
  • Gallo RL; Department of Dermatology, University of California San Diego, San Diego, Calif.
  • Hata T; Department of Dermatology, University of California San Diego, San Diego, Calif.
  • Schneider LC; Division of Immunology, Boston Children's Hospital, Boston, Mass.
  • Paller AS; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Pediatrics (Dermatology), Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill.
  • Ong PY; Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles, Los Angeles, Calif; Keck School of Medicine, University of Southern California, Los Angeles, Calif.
  • Spergel JM; Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa.
  • Guttman-Yassky E; Icahn School of Medicine at Mount Sinai, New York, NY.
  • Leung DYM; Division of Allergy and Immunology, Department of Pediatrics, National Jewish Health, Denver, Colo.
  • Beck LA; Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center, Rochester, NY.
  • Gignoux CR; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo.
  • Mathias RA; Department of Medicine, Johns Hopkins University Department of Medicine, Baltimore, Md.
  • Barnes KC; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo. Electronic address: Kathleen.Barnes@cuanschutz.edu.
J Allergy Clin Immunol ; 149(1): 145-155, 2022 01.
Article en En | MEDLINE | ID: mdl-34111454
ABSTRACT

BACKGROUND:

While numerous genetic loci associated with atopic dermatitis (AD) have been discovered, to date, work leveraging the combined burden of AD risk variants across the genome to predict disease risk has been limited.

OBJECTIVES:

This study aims to determine whether polygenic risk scores (PRSs) relying on genetic determinants for AD provide useful predictions for disease occurrence and severity. It also explicitly tests the value of including genome-wide association studies of related allergic phenotypes and known FLG loss-of-function (LOF) variants.

METHODS:

AD PRSs were constructed for 1619 European American individuals from the Atopic Dermatitis Research Network using an AD training dataset and an atopic training dataset including AD, childhood onset asthma, and general allergy. Additionally, whole genome sequencing data were used to explore genetic scoring specific to FLG LOF mutations.

RESULTS:

Genetic scores derived from the AD-only genome-wide association studies were predictive of AD cases (PRSAD odds ratio [OR], 1.70; 95% CI, 1.49-1.93). Accuracy was first improved when PRSs were built off the larger atopy genome-wide association studies (PRSAD+ OR, 2.16; 95% CI, 1.89-2.47) and further improved when including FLG LOF mutations (PRSAD++ OR, 3.23; 95% CI, 2.57-4.07). Importantly, while all 3 PRSs correlated with AD severity, the best prediction was from PRSAD++, which distinguished individuals with severe AD from control subjects with OR of 3.86 (95% CI, 2.77-5.36).

CONCLUSIONS:

This study demonstrates how PRSs for AD that include genetic determinants across atopic phenotypes and FLG LOF variants may be a promising tool for identifying individuals at high risk for developing disease and specifically severe disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica / Proteínas Filagrina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Infant / Male Idioma: En Revista: J Allergy Clin Immunol Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica / Proteínas Filagrina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Infant / Male Idioma: En Revista: J Allergy Clin Immunol Año: 2022 Tipo del documento: Article